KHK4951 eye drops maintained vision in most nAMD patients at 52 weeks
KHK4951 eye drops maintained vision in 65-69% of Phase 2 patients with nAMD without rescue injections at 52 weeks, with stable safety and tolerability, per the source.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.